What is the 13F Pro Quality Score for TLX?

13F Pro ranks Telix Pharmaceuticals Ltd (TLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TLX's current score at https://13fpro.ai/company/TLX (free sign-up required for the full ranking).

Which hedge funds own the most TLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TLX include FMR, LAZARD ASSET MANAGEMENT, PORTLAND INVESTMENT COUNSEL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TLX as soon as new 13F filings post.

Where does 13F Pro source TLX data?

All Telix Pharmaceuticals Ltd fundamentals and ownership data come directly from SEC EDGAR. Telix Pharmaceuticals Ltd files with the SEC under CIK 2007191. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TLX in?

Telix Pharmaceuticals Ltd (TLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TLX research updated on 13F Pro?

TLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Telix Pharmaceuticals Ltd(TLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 2007191 TLX stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

36.9/100

Rank #2,248 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TLX Scores 37/100

exact factor attribution · 2026-09-11

TLX's composite is driven by institutional flow and shareholder dilution, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.3 pts

96th pct

Shareholder dilution

+2.1 pts

93th pct

Earnings growth

-1.0 pts

30th pct

Capital efficiency

-1.9 pts

32th pct

Earnings quality

-2.0 pts

30th pct

Profitability

-2.7 pts

32th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TLX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Telix Pharmaceuticals Ltd (TLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLX at 36.9/100 on a 32-signal composite quality model, placing it at rank #2,248 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Telix Pharmaceuticals Ltd reports quarterly revenue of $803.8M, net income of $-7.1M. Top institutional holders of TLX by reported 13-F value include FMR, LAZARD ASSET MANAGEMENT, PORTLAND INVESTMENT COUNSEL, based on the most recent SEC filings. TLX trades on the Nasdaq exchange and files with the SEC under CIK 2007191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Telix Pharmaceuticals Ltd directly from SEC EDGAR. Telix Pharmaceuticals Ltd's 13F Pro composite quality score has ranged between 35 and 37 since 2026, currently 36.9 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.

Revenue

FY 2025

$803.8M

Net Income

FY 2025

$-7.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+55.6% YoY

$803.8MFY 2025

FY22 $160.1MFY23 $333.0MFY24 $516.6MFY25 $803.8M

Total Assets

+23.8% YoY

$1.16BFY 2025

FY22 —FY23 $277.3MFY24 $940.4MFY25 $1.16B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$803.8M +55.6%	$516.6M +55.1%	$333.0M +108.0%	$160.1M	—
Total Assets	$1.16B +23.8%	$940.4M +239.2%	$277.3M	—	—

Get alerted when TLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Telix Pharmaceuticals Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TLX

FMR LLC
$6.5M561,206 sh
LAZARD ASSET MANAGEMENT LLC
$3.3M284,207 sh
PORTLAND INVESTMENT COUNSEL INC.
$3.1M266,200 sh
Private Advisor Group, LLC
$2.3M197,250 sh
MARSHALL WACE, LLP
$2.2M189,188 sh
MORGAN STANLEY
$1.9M165,978 sh
Integrated Wealth Concepts LLC
$1.9M164,397 sh
Hennion & Walsh Asset Management, Inc.
$1.7M150,138 sh
UBS Group AG
$1.6M134,698 sh
BLAIR WILLIAM & CO/IL
$1.4M122,985 sh

Fund	Value	Shares
FMR LLC	$6.5M	561,206
LAZARD ASSET MANAGEMENT LLC	$3.3M	284,207
PORTLAND INVESTMENT COUNSEL INC.	$3.1M	266,200
Private Advisor Group, LLC	$2.3M	197,250
MARSHALL WACE, LLP	$2.2M	189,188
MORGAN STANLEY	$1.9M	165,978
Integrated Wealth Concepts LLC	$1.9M	164,397
Hennion & Walsh Asset Management, Inc.	$1.7M	150,138
UBS Group AG	$1.6M	134,698
BLAIR WILLIAM & CO/IL	$1.4M	122,985

Companies Similar to TLX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PHAR

Pharming Group N.V.

AI score

Similar quality profile

HCM

HUTCHMED (China) Ltd

AI score

Shared smart-money ownership · 1 shared holders

XY Capital Ltd

TAK

TAKEDA PHARMACEUTICAL CO LTD

AI score

Similar quality profile

PHG

KONINKLIJKE PHILIPS NV

AI score

Similar quality profile · 1 shared holders

XY Capital Ltd

PIII

P3 Health Partners Inc.

AI score

Similar quality profile

IVA

Inventiva S.A.

AI score

Similar quality profile

SNN

SMITH & NEPHEW PLC

AI score

Similar quality profile · 1 shared holders

SummitTX Capital, L.P.

RDY

DR REDDYS LABORATORIES LTD

AI score

Similar quality profile · 2 shared holders

XY Capital Ltd NLB Skladi, upravljanje premozenja, d.o.o.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TLX on your watchlist

Track score changes the day Telix Pharmaceuticals Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TLX a good stock to buy?

13F Pro's AI-powered analysis of Telix Pharmaceuticals Ltd (TLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TLX are available on the TLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TLX is classified as a mid company.

Which hedge funds own TLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Telix Pharmaceuticals Ltd's investment landscape.